dm+d
429368003
Articles
Supply of emtricitabine/tenofovir disoproxil and raltegravir tablets for HIV Post Exposure Prophylaxis (HIV PEP): PGD template
5 October 2021A PGD template developed by SPS and the British Association of Sexual Health and HIV (BASHH) and British Association of HIV (BHIVA).
Switching between liquid and tablet/capsule formulations - Which medicines require extra care?
19 July 2021For a small number of medicines, there are differences in equivalent doses of oral formulations of the same medicine. This needs to be considered when…
Safety in Lactation: HIV infection
23 September 2020Breastfeeding by HIV-positive mothers may cause HIV infection in the infant and should be avoided where possible. The use of HIV drugs during breastfeeding is…
Raltegravir 600 mg once daily
29 March 2018Raltegravir (Isentress®) is an integrase strand transfer inhibitor licensed in combination with other antiretroviral drugs for the treatment of Human Immunodeficiency Type 1 (HIV-1) infection.…
Medicine Compliance Aid Stability
IsentressMerck Sharp & Dohme Ltd
Merck Sharp & Dohme Ltd
Isentress
Tablets 400mg
G1 · Green 1Stability data indicates that the drug is suitable for CAs and there are no theoretical concerns with the product.
No special precautions for storage
Manufacturer confirms stability.
5 August 2015
IsentressMerck Sharp & Dohme Ltd
Merck Sharp & Dohme Ltd
Isentress
Tablets chewable 25mg, 100mg
R1 · Red 1Stability data indicates that the drug is not suitable for CAs.
Unsuitable
Chewable tablets stored with dessicant in original pack.
15 February 2022
Lactation Safety Information
Specialist drug/complex disease area for which expert advice is recommended
21 September 2020